Latest Protocols For Mesothelioma

Treatment Options, Patient Profiles, Clinical Trials, Compensation, Surgical Choices

• Oncologists Profit On Chemotherapy Drugs They Prescribe To Cancer Patients (10/4/06)
• England Limits Usage of Alimta for Mesothelioma, Eli Lilly Appeals (6/26/06)
• Alimta® and Paraplatin® Effective and Well-Tolerated in Mesothelioma (3/22/06)
• Against the Odds: Given Just Months to Live, Ragland Man Gets Hope for Future from New Chemotherapy Treatment. Ragland, AL (4/2/05)
• Pemetrexed in Malignant Pleural Mesothelioma (1/31/05)
• Red Tape Slows PBS Approval (1/3/05)
• Alimta(R) Showed Advances over Taxotere(R) in Second-Line Non-Small Cell Lung Cancer Study (5/3/04)
• Puget Sound Cancer Centers Plays Significant Role in Clinical Testing Of Newly Approved Cancer Drug; FDA Approves Alimta for Treatment of Asbestos-Related Cancer (3/19/04)
• FDA OKs Lilly Drug for Asbestos-Related Cancer (2/5/04)
• Lilly Expects FDA to Decide on Alimta by March 31 (12/4/03)
• Lilly Initiative Provides Investigational Agent Free of Charge for Medically Eligible Patients with Mesothelioma (10/15/03)
• ALIMTA Plus Gemcitabine (Gemzar) for Patients with Malignant Pleural or Peritoneal Mesothelioma who have not had previous chemotherapy (9/19/03)
• Drug Combination Extends Survival in Mesothelioma (7/16/03)
• Thoracic Expert: Patients With Asbestos-Related Cancer Report Better Quality of Life With Alimta+Cisplatin (6/13/03)
• ASCO Reports on Intracavitary Hyperthermic Chemo, FDG-PET Scan Prognostication, and Alimta/Cisplatin Quality of Life (6/12/03)
• A List of Doctors Offering Alimta on Expanded Access Program (2/5/03)
• Open - Label Study of Alimta (Pemetrexed) Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma. (New York, NY) (2/3/03)
• Alimta Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial. (New York, NY) (2/3/03)
• Open-Label Study of Alimta (Pemetrexed) and Cisplatin in Chemonaive Patients with Malignant Pleural Mesothelioma. Southwestern Regional Medical Center, Tulsa, OK (1/13/03)
• MARF Doctor Hails Alimta as "A New Standard Therapy" for Treating Mesothelioma; Lilly Makes Drug Available through Expanded Access Program. Indianapolis, Indiana, November 14, 2002 (11/20/02)
• Pemetrexed - New Chemotherapy Promising for Asbestos Lung Cancer (8/14/02)
• Lilly Offers Alimta On Expanded Access Basis (7/10/02)
• Lilly Offers Asbestos Cancer Drug to Some (7/9/02)
• Alimta Touted as "New Standard of Care" for Uresectable Mesothelioma (5/29/02)
• Eli Lilly Boosted By Drug Success (5/28/02)
• Lilly Says Anticancer Drug Prolonged Lives of Patients (5/20/02)
• Lilly, Patients Hope Drug For Asbestos-related Cancer Gains OK (5/16/02)
• Lilly Outlines Its Strategy to Become the Pharmaceutical Growth Company of the Decade (10/24/01)
• 61 Years Old, Diagnosed in 1999 - "Still well enough to to have an almost normal life" - England (7/12/01)
• Multitargeted Antifolate (ALIMTA) Abstracts (4/12/01)
  • Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. -- Biochem Pharmacol (4/1/01)
  • Gemcitabine and Pemetrexed disodium in treating breast cancer. -- Oncology (Huntingt) (2/15/01)
  • Pemetrexeda multitargeted antifolate agent with promising activity in solid tumors. -- Ann Oncol (10/11/00)
  • Multitargeted antifolate (ALIMTA)pharmacokinetics of intraperitoneal administration in a rat model. -- Eur J Surg Oncol (11/26/00)
  • Gemcitabine/ALIMTA in locally advanced or metastatic nonsmallcell lung cancer. Ettinger DS. -- Oncology (Huntingt) (7/14/00)
  • Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. -- J Clin Oncol (4/18/00)
  • Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. -- 1Clin Cancer Res (3/6/00)
  • Frontline treatment of advanced nonsmallcell lung cancer with ALIMTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatina multicenter phase II trial -- Ann Oncol (4/11/00)
• ALIMTA/Cisplatin vs. Cisplatin, Phase III Trial Locations Nationwide (4/11/01)
  As of April 11, 2001, these are the locations of the Phase III clinical trial using ALIMTA/Cisplatin vs. Cisplatin. You will need to contact the specific location to determine the availability of the trial and your eligibility. Please advise us of your experience, good or bad, in contacting these doctors and/or hospitals. We are interested in learning which trials are available and which are not.
• Multi-Targeted Antifolate, or "ALIMTA", is made by Eli Lilly and it is being used in Phase III clinical trials for mesothelioma patients (6/12/00)

• ITL Cancer Clinic
  Formally the Immuno-Augmentative Therapy Clinic (IAT). Objective is to activate the body's immune system to target and kill the cancer cells. The treatment protocol involves the use of a serum that is administered daily based on an analysis of the patient's blood.
• Cancell
• Gerson Therapy
• American Biologics- Mexico SA Medical Center, Tijuana, Mexico

• Cell Genesys Initiates New Trial of Lung Cancer Drug - GVAC (6/30/04)
• A Phase 2 Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) ("GVAX® Lung Cancer Vaccine") with and without Low-Dose Cyclophosphamide in Advanced Stage Non Small-Cell Lung Cancer (6/30/04)
• GVAC Lung Cancer Vaccine (6/30/04)
• Genetic Marker Promises Personalized Cancer Treatment (6/21/04)
• Cancer Advances: News from the 2004 ASCO Annual Meeting: Drug Shows Activity in Advanced BAC (6/9/04)
• Veglin Phase I Trial Shows Potential in Fighting Angiogenesis and Tumor Progression (6/7/04)
• New IRESSA(R) (Gefitinib) Data Presented in Bronchioalveolar Lung Cancer (6/5/04)
• Retrospective Analysis of Response to Gefitinib ('Iressa', ZD1839) in Pre-treated Patients with Non-small-cell Lung Cancer (NSCLC): Influence of Histologic Subtype and Smoking History (6/1/04)
• Discovery Promises Better Use of Iressa for Lung Cancer (4/29/04)
• Tarceva®, Formerly Known as OSI-774, An Epidermal Growth Factor Receptor (EGFR) Inhibitor (7/29/02)
• Next Era of Cancer Therapy Aims to Separate Cancer From Blood Supply (5/19/03)
• FDA Approves Last Chance Drug for Lung Cancer (5/6/03)
• Confidence High In Experimental Antitumor Agent Tarceva Despite Iressa Failure (10/11/02)
• AstraZeneca Drug Trial Fails, Shares Down (Iressa) (8/21/02)
• New Pill (Iressa) May Improve Lung Cancer (5/20/02)
• ZD 1839 - Iressa (4/17/02)
• Mesothelioma: Insights and Observations (10/2/00 )
• BioPulse Announces Angiogenesis Cancer Treatment (8/20/00)
• Anticancer Mechanisms for Endostatin Revealed at the Annual Meeting Of American Association for Cancer Research (5/4/00)
• Indiana University Opens Angiogenesis Trial for Breast Cancer Patients (3/8/00)

• Angiogenesis Inhibitors (12/21/01)
• New Cancer Drugs Disappointing (Angiostatin and Endostatin) (5/14/01)
• Early Report Shows Endostatin No Magic Bullet Against Cancer (11/10/00)
• "Eligibility Criteria for Phase I Endostatin Trial at Univ. Wisconsin" Also see trial info for Dana Farber (Boston) and MD Anderson (Houston) (5/24/00)
• Endostatin Clinical Trial Underway at MD ANDERSON (Houston) and DANA FARBER (Boston) (11/5/99)
  Endostatin Phase I Trial Offered:
  ** The University of Texas, M.D. Anderson Cancer Center. Please call (800) 622-8922.
  ** The University of Wisconsin. Please call (800) 392-1611
• For up-to-date information about anti-angiogenis research, including an update on the drug endostatin, along with a listing of agents currently in clinical trials.

• New Drugs Starve Cancer Tumors (3/15/04)

• Not Ready for Mesothelioma Patients (12/14/98)
• Phase III Trial Cancer Interaction Study using Bayer 12-9566 in Rochester (Mayo) and San Antonio (Brook Army Medical Center) (12/3/98)
• Phase 1 Trial of LY231514 (12/99)

• Celebrex and VEGF Inhibitor Clinical Trial for MM May Be Useful - April 10, 2004 (9/20/04)
  Celecoxib may have antitumor properties in MM and provide a rationale for the therapeutic use of celecoxib in combination with a selective VEGF inhibitor.
• Celebrex Inhibits mesothelioma Cell Growth in Lab Studies (5/12/04)

• Phase I Trial For Mesothelioma (BASF Pharma) (9/8/00)

• Dr. Ann Weinacker. Stanford University Medical Center. Dr. Weinacker is interested in therapies for malignant pleural mesothelioma and is involved in a phase I trial of gene therapy for malignant mesothelioma. (4/14/03)
• Preclinical Data of Introgen's INGN 241 Demonstrate Broad Anti-Cancer Activity In Multiple Tumor Types as Monotherapy and in Combination; Update on Gene Therapy Research at MDA under Dr. Roy Smythe. (6/14/01)
• Penn Pursues Testing on Genes: (1/21/01)
• Australia Doctors: Gene Therapy (IL-12) Retards Mesothelioma in Mice But Causes Side Effects (9/27/99)
• Gene Therapy Updates: Dr. Daniel Sterman, (6/98)
• Son of Insulator with MM Helps Father Enroll in Gene Therapy Program at LSU - New Orleans, LA.
• Gene Therapy Phase I Study at LSU Medical Center: Dr. Paul Schwarzenberger, (12/97)
  • Antitumor Activity With Gene Modified Tumor Cells: Dr. Paul Schwarzenberger, (8/14/98)
  • Brave 49 Year Old Woman Shows Response to Gene Therapy, But Tumors Return. New Orleans, LA (8/3/99)
• Update on UPENN GENE THERAPY Phase II Protocol: After two years, Donald Hardy's Tumor Stabilized (10/3/97)
• Update on Dr. Daniel Sterman and Gene Therapy: (10/6/97)
• UPENN Gene Therapy
• Primer on Immunotherapy: The New Frontier.

• What Is Gleevec? (11/5/02)
• Gleevec Medical Abstracts and Other Information (2001-2002)
  • New approaches for mesotheliomabiologics, vaccines, gene therapy, and other novel agents. (9/6/02)
  • Functional Tyrosine Kinase Inhibitor Profiling A Generally Applicable Method Points to a Novel Role of Platelet-Derived Growth Factor Receptor-beta in Tuberous Sclerosis. (9/6/02)
  • Severe periorbital edema secondary to STI571 (Gleevec). (9/6/02)
  • Protein kinases as targets for anticancer agentsfrom inhibitors to useful drugs. (9/6/02)

• Cell Genesys Initiates New Trial of Lung Cancer Drug - GVAC (6/30/04)

• Interferon, What is it?
• Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. (1/2004)
• Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. (6/2003)
• Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. (8/2002)
• Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study (6/2002)
• Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). (8/2001)
• Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. (3/2001)

• Interleukin-4 Receptor Cytotoxin as Therapy for Human Malignant Mesothelioma Xenografts (7/29/04)
• Biological Response Modifiers (7/4/04)
• Experimental Protocol: Immunization against Cancer Cells using Interleukin-2 and Macrophage Colony Stimulating Factor, Mike McCoy, Ph.D.
• Helpful Fact Sheet

• MG98's Preclinical Antitumor Activity and Safety, and Phase 1 Clinical Profile Demonstrated in two Mesothelioma Patients (11/2/01)

• ONCONASE ® plus doxorubicin vs. doxorubicin for patients with Malignant Pleural or Peritoneal Mesothelioma who have had no more than one prior chemotherapy regimen. (3/8/04)
• Update on Phase III Program of ONCONASE(R) for The Treatment of Patients with Unresectable Malignant Mesothelioma (4/18/02)
• Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase (Onconase) in Patients With Unresectable Malignant Mesothelioma (12/31/01)
• Onconase Is Available in Europe to Patients With Malignant Mesothelioma (7/13/01)
• Mesothelioma: Insights and Observations (10/2/00 )
• Phase III Results: ONCONASE Vs. Doxorubicin Presented At ASCO Meeting: ONCONASE Shows Survival Benefit in Patients with Malignant Mesothelioma (5/25/00 )
• Dr. Mikulski Explains Why mesothelioma Patients Should Participate in Phase III Clinical Trial (Onconase/Doxorubicin vs. Doxorubicin). (8/6/99)
• Onconase Phase III Clinical Trial Eligibility Criteria and Treatment Centers Coast to Coast. (7/29/99 )
• Updated Changes to Dr. Taub's Protocol and Patient Search for Onconase Trials.
• ALFACELL Announces ONCONASE Phase II Malignant Mesothelioma Results, (3/23/99)
• The Use of Onconase (ONC) for Patients (PTS) with Advanced Malignant Mesothelioma (MM)
• Onconase

• Oxaliplatin Plus Raltitrexed Active in Mesothelioma (7/16/03)

• New Treatment Options For Some Difficult Cancers Improve Survival and Quality of Life (3/7/05)
• R. McQuellon, et al, "Long-Term Survivorship and Quality of Life after Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis" Annals of Surgical Oncology, 10(2):155-162, 2003 (9/29/04)
• Treatment and Prevention of Malignant Ascites Associated with Disseminated Intraperitoneal Malignancies by Aggressive Combined-Modality Therapy (9/29/04)
• Intraperitoneal Hyperthermic Chemotherapy (IPHC) for Peritoneal Carcinomatosis and Malignant Ascites. Creighton University Medical Center (CUMU) Cancer Center (9/29/04)
  • Letter to Prospective Patients at the Creighton University Medical Center Cancer Center
  • New Patient Checklist
    • Notice of Privacy Rules
    • Cancer Center Registration Form
    • Review of Systems and Health History
    • Referring Doctors Form
    • Map from Airport to CUMC
• Cytotoxic Activity of the Recombinant Anti-mesothelin I immunotoxin, SS1(dsFv)PE38, Towards Tumor Cell Lines Established from Ascites of Patients with Peritoneal Mesotheliomas (7/29/04)
• Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy (12/30/03)
• Phase II Trial of Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for Treatment of Peritoneal Mesothelioma (11/14/01)
• New Trial Using Tri-Modal Therapy for Peritoneal Mesothelioma in New York with Dr. Robert N. Taub.

• Aronex Pharmaceuticals Receives Orphan Drug Designation for Mesothelioma Indication for Platar (now "Aroplatin") (11/10/99)
• Platar Phase II Protocol for Pleural and Peritoneal Mesothelioma Open in Houston, Texas and New York, New York, (5/7/99)
• Letter from Dr. Roman Perez-Solar Regarding L-NNDP, (6/30/99)
• Phase II Trial using Platar Shows Promise; MD Anderson Hospital, Houston, TX; Kaplan Cancer Center, NYC, (5/17/99)
• Phase I Study of Platar on Peritoneal Mesothelioma, M.D. Anderson, (5/99)
• Abstract of Phase I Study at M.D. Anderson Using L-NDDP (PLATAR), (3/97)

• New Drug Shows Promise in Killing mesothelioma tumors and Boosting Immune System, Australia (6/29/04)

• Phase I, Pharmacokinetic, and Pharmacogenetic Study of TAS-103 (6/28/00)

• Taxotere (docetaxel) (4/23/02)
• Jefferson Cancer Center - Taxotere for Malignant Mesothelioma: A phase II Study of the Eastern Cooperative Oncology
  • Taxotere for MM: A phase II study suspended on April 25, 1997

• TLK286 Phase 1 Results At American Society of Clinical Oncology Meeting (6/29/01)

• Research Shows Anti-Cancer Drug is Safe (Veglin) (7/15/04)
• Veglin Phase I Trial Shows Potential in Fighting Angiogenesis and Tumor Progression (6/7/04)

---

AMERICAN INSTITUTE FOR CANCER RESEARCH

• Nutrition and the Cancer Survivor: Guidelines For Eating To Prevent A Recurrence Of Cancer (9/18/01)

NATIONAL CANCER INSTITUTE

• Eating Healthy -- Eating Hints for Cancer Patients; Before, During and After Treatment (1/16/01)

• SV40 Sequences in Mesothelioma Predict Poorer Survival (10/2/00)
• SV40, Asbestos and Mesothelioma: Hot Potato, Red Herring or Silver Bullet? (9/18/00)
• Potential Vaccine for Mesothelioma? (3/4/99)

---

* * * * * * * * * * *
Neither the Law Offices of Roger G. Worthington nor its clients herein (including clients of other law firms) intend to waive the attorney-client privilege by posting information about these clients herein. The information contained herein is intended to educate and inform asbestos cancer patients and their families of potential medical and legal options. Roger Worthington is not a medical doctor. Patients are advised to consult with a medical doctor and/or an attorney if they have questions regarding this information. The opinions expressed herein by persons other than Roger Worthington are not necessarily endorsed by the Law Offices of Roger G. Worthington, P.C. This is an open forum.

* * * * * * * * * * *